BioSpace News Archive

Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2023 second quarter ended December 31, 2022, on Tuesday, February 14, 2023 after the close of the stock market, and host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results.

Varex Imaging Corporation announced its unaudited financial results for the first quarter of fiscal year 2023.

Prothena Corporation plc (NASDAQ:PRTA) today announced positive topline Phase 1 single ascending dose (SAD) study results for PRX005, a potentially best-in-class investigational tri-epitopic antibody for the treatment of Alzheimer’s disease that specifically binds with high affinity to the R1, R2, and R3 repeats within the microtubule binding region (MTBR) of tau and targets both 3R and 4R tau isoforms

Conformal Medical, Inc. announced today the presentation of the one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS® System in patients under conscious sedation without general anesthesia.

Medexus Pharmaceuticals plans to host a conference call at 8:00 am Eastern Time on Thursday, February 9, 2023 to discuss Medexus’s results for its third fiscal quarter ended December 31, 2022.

Sarepta Therapeutics, Inc. granted equity awards on January 31, 2022 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 40 individuals hired by Sarepta in January 2023.

Nordic Nanovector ASA (“Nordic Nanovector” or the “Company”) announces that Ludvik Sandnes, former Chairperson of Nordic Nanovector, has been appointed interim Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of the Company as from 1 February 2023.

The American Diabetes Association® announced the two winners of the Pathway to Stop Diabetes® grants, a five-year grant to support breakthroughs in translational science, clinical science, technology, care, and potential cures in the field of diabetes.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”) today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional accredited investor.

Aluna, the award-winning lung health management platform, announced it has completed a $15.3 million Series B round of financing to continue growing its solution among doctors and patients managing asthma, cystic fibrosis and COPD.